



Please amend the claims (10/064,698, Confirmation No. 9324, art unit 1615) as follow and consider our remarks:

1- (Amended) Method for enhancing hair growth or diminishing hair loss or alopecia, in mammals, comprising administering topically to the skin a mixture of a nitric oxide (NO) donor such as minoxidil, or 6-(1-piperidiny)pyrimidine-2,4-diamine 3-oxide and a cyclic guanosine 3',5'-monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) inhibitor such as sildenafil citrate ($C_{22}H_{30}N_6O_4S \cdot C_6H_8O_7$) in a dermatologically acceptable solution mix.

2- (Original) Method according to claim 1, wherein said topical dermatological compound is in the form of an aqueous solution or suspension, or in the form a gel, a shampoo, an ointment or a cream in a pharmaceutically acceptable dermatological vehicle or carrier to be applied to the mammalian skin.

3- (Amended) Method according to claim 1, wherein the Nitric Oxide (No) releasing agent in said dermatological mix is glyceryl trinitrate or nitroglycerine ($C_3H_5N_3O_9$)

4- (Amended) Method according to claim 1, wherein the Nitric Oxide (No) releasing agent in said dermatological mix is L-arginine or ($C_6H_{14}N_4O_2$).

5- (Amended) Method according to claim 1, wherein the Nitric Oxide (No) releasing agent in said dermatological mix is a isosorbide dinitrate or ($C_6H_8N_2O_8$)

6- (Amended) Method according to claim 1, wherein the Nitric Oxide (No) releasing agent in said dermatological mix is nitroprusside or ($Na_2Fe(CN)_5NO \cdot 2H_2O$)

7- (Withdrawn) Method according to claim 1, wherein the No releasing agent in said dermatological mix is S-nitrosylated-proteins/peptides.

8- (Withdrawn) Method according to claim 1, wherein the No releasing agent in said dermatological mix is S-nitrosylated oligosaccharides and polysaccharides.

9- (Withdrawn) Method according to claim 1, wherein the No releasing agent in said dermatological mix is a Nonoate compounds such as piperazines 2 and diazeniumdiolates.

10- (Withdrawn) Method according to claim 1, wherein the No releasing agent in said dermatological mix is an inorganic nitroso compound such as sodium nitroprusside.

11- (Withdrawn) Method according to claim 1, wherein the No releasing agent in said dermatological mix is Sydnominines.

12- (Withdrawn) Method according to claim 1, wherein the No releasing agent in said dermatological mix is L-arginine (which does not release NO directly, but rather is an enzyme substrate which leads to the formation of nitric oxide in vivo).

- 13- (Withdrawn) Method according to claim 1, wherein the No releasing agent in said dermatological mix is 1,3-(nitrooxymethyl)phenyl 2-hydroxybenzoate isosorbide dinitrate.
- 14-(Withdrawn) Method according to claim 1, wherein the No releasing agent in said dermatological mix is pyrimidine (also known as Minoxidil or Rogaine.sup.RTM).
- 15- (Withdrawn) Method according to claim 1, wherein the cGMP specific PDE-5 inhibitor in said dermatological mix is (sildenafil) also known as 1-[[3-(6,7dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-y- l)-4 ethoxyphenyl]sulphonyl]-4-methylpiperazine.
- 16- (Withdrawn) Method according to claim 1, wherein the cGMP specific PDE-5 inhibitor in said dermatological mix is sildenafil citrate, (Viagra.sup.RTM) also known as 1-[[3-(6,7dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyri- midin-5-yl)-4 ethoxyphenyl]sulphonyl]-4-methylpiperazine citrate.
- 17- (withdrawn) Method according to claim 1, wherein the cGMP specific PDE-5 inhibitor in said dermatological mix is 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphony- l)-2-n-propoxyphenyl]-2-(pyridin-2yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]- pyrimidin-7-one.
- 18- (Withdrawn) Method according to claim 1, wherein the cGMP specific PDE-5 inhibitor in said dermatological mix is 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-met- hoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3 pyridylsulphonyl]-4-ethylpip-erazine.
- 19- (withdrawn) Method according to claim 1, wherein said topical dermatological mix is in the form of an aqueous solution and further contains one or more tonicity adjusting agents, one or more buffers and one or more antioxidants.
- 20- (Withdrawn) Method according to claim 1, wherein said topical dermatological mix further contains one or more antimicrobial agents.
- 21- (Original) The composition according to claim 1, wherein said dose is in pill form for oral administration.
- 22- (Original) The method according to claim 1, wherein said topical dermatological mix further contains one or more combinations of NO donors and cGMP PDE5 inhibitors.
- 23- (Original) The method according to claim 1, wherein said topical dermatological mix further contains one or more weight or volume percentage combinations of NO donors and cGMP PDE5 inhibitors.
- 24- (Withdrawn) A composition according to claim 1 wherein said composition also includes a pharmaceutically effective vehicle for said compound.
- 25- (Original) A composition according to claim 1 used in veterinary preparations or feeds to increase the rate of growth of fur (pelt) in certain fur bearing animals and to retard shedding and molting.

Thus the new set of claims is:

1- Method for enhancing hair growth or diminishing hair loss or alopecia, in mammals, comprising administering topically to the skin a mixture of a nitric oxide (NO) donor such as minoxidil, or 6-(1-piperidinyl)pyrimidine-2,4-diamine 3-oxide and a cyclic guanosine 3',5'-monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) inhibitor such as sildenafil citrate ($C_{22}H_{30}N_6O_4S \cdot C_6H_8O_7$) in a dermatologically acceptable solution mix.

2- Method according to claim 1, wherein said topical dermatological compound is in the form of an aqueous solution or suspension, or in the form a gel, a shampoo, an ointment or a cream in a pharmaceutically acceptable dermatological vehicle or carrier to be applied to the mammalian skin.

3- Method according to claim 1, wherein the NO releasing agent in said dermatological mix is glyceryl trinitrate or nitroglycerine ($C_3H_5N_3O_9$)

4- Method according to claim 1, wherein the NO releasing agent in said dermatological mix is L-arginine or ($C_6H_{14}N_4O_2$).

5- Method according to claim 1, wherein the NO releasing agent in said dermatological mix is a isosorbide dinitrate or ($C_6H_8N_2O_8$)

6- Method according to claim 1, wherein the NO releasing agent in said dermatological mix is nitroprusside or ($Na_2Fe(CN)_5NO \cdot 2H_2O$)

7-The composition according to claim 1, wherein said dose is in pill form for oral administration.

8-The method according to claim 1, wherein said topical dermatological mix further contains one or more combinations of NO donors and cGMP PDE5 inhibitors.

9-The method according to claim 1, wherein said topical dermatological mix further contains one or more weight or volume percentage combinations of NO donors and cGMP PDE5 inhibitors.

10- A composition according to claim 1 used in veterinary preparations or feeds to increase the rate of growth of fur (pelt) in certain fur bearing animals and to retard shedding and molting.

These claims have been revised and amended or withdrawn based on the Examiners' election/restrictions under 35 USC 103, 35 USC 112.